Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents

Pediatr Infect Dis J. 2017 Apr;36(4):401-404. doi: 10.1097/INF.0000000000001491.

Abstract

We determined hepatitis B virus (HBV) suppression rates among 18 lamivudine (3TC)-experienced HBV-human immunodeficiency virus-coinfected adolescents after treatment with tenofovir disoproxil fumurate (TDF). At TDF initiation, their median age was 17.6 years, and duration of 3TC exposure was 7.3 years. Eleven patients (61%) achieved HBV DNA <60 IU/mL after 48 weeks on TDF and 3TC which was similar to adult studies, although hepatitis B surface antigen loss or hepatitis B envelope antigen seroconversion did not occur.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Adult
  • Antiviral Agents / therapeutic use*
  • Child
  • Coinfection / drug therapy*
  • Coinfection / epidemiology
  • Coinfection / virology
  • DNA, Viral / blood
  • HIV Infections / drug therapy*
  • HIV Infections / epidemiology
  • HIV Infections / virology
  • Hepatitis B / drug therapy*
  • Hepatitis B / epidemiology
  • Hepatitis B / virology
  • Humans
  • Lamivudine / therapeutic use
  • Longitudinal Studies
  • Prospective Studies
  • Tenofovir / therapeutic use*
  • Young Adult

Substances

  • Antiviral Agents
  • DNA, Viral
  • Lamivudine
  • Tenofovir